Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal ALN-RSV01 in experimentally induced RSV infection (adult volunteers)
2006-006902-27Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2008
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing ALN-RSV01 intranasal with Placebo intranasal (2 arms). Primary endpoint: Safety and tolerability of intranasal ALN-RSV01 versus placebo. Started Dec 2008; status: completed.
02
Drugs
asvasiran
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2006-006902-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006902-27.